Cellectar Biosciences (CLRB) Misses Q2 EPS by 326c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq hits record high as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts CLRB Hot Sheet
Join SI Premium – FREE
Cellectar Biosciences (NASDAQ: CLRB) reported Q2 EPS of ($3.39), $3.26 worse than the analyst estimate of ($0.13).
For earnings history and earnings-related data on Cellectar Biosciences (CLRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs sees AI investment adding to European growth in 2026
- Harley-Davidson (HOG) call put ratio 1 call 4.5 puts with a focus on October 26.50 puts, share price up 7.9%
- Align Technology (ALGN) call put ratio 1 call 2.9 puts with a focus on November 140 puts
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
